Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Completes SAB Buy; Added to Nasdaq-100

NEW YORK (GenomeWeb News) – Qiagen has completed its acquisition of SABiosciences, a privately held developer of disease- and pathway-focused PCR assay panels, for around $90 million.

Qiagen announced the deal in early November, saying at that time that it expects SABiosciences' products to be highly synergistic with its September acquisition of UK-based companion diagnostics firm DxS.

SABiosciences employs around 100 people and its primary product family includes more than 100 real-time PCR assay panels for analyzing DNA, RNA, epigenetic, and microRNA targets in biological pathways associated with specific diseases such as cancer, diabetes, and immune and cardiovascular disorders; as well as with pathways such as apoptosis, signal transduction, and toxicology.

Qiagen said that it expects SABiosciences to add $24 million in sales in 2010. It also said that it expects to incur charges of roughly $.02 in earnings per share related to costs and expenses associated with the acquisition. Qiagen also expects the acquisition to be significantly accretive to its adjusted EPS in 2011.

In a separate announcement today, Qiagen said that it has been added to the Nasdaq-100 Index, effective Dec. 21. The Index includes the top 100 non-financial securities listed on the Nasdaq stock market based on market capitalization.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.